This is the authors' abstract. We don't add key points for this paper.
Background and Aim: Due to a large part to its aggressive invasiveness and quick growth, lung cancer continues to rank among the world’s top causes of cancer-related death. The pathophysiology of this disease has been linked to ion channels, specifically voltage-gated sodium channels (VGSCs), according to the recent research. In a number of malignancies, including lung adenocarcinoma, VGSCs are linked to altering membrane potential and increasing metastasis. AahII toxin, a highly selective VGSCs blocker, derives from the venom of Androctonus australis hector scorpion. However, systemic toxicity with repeated administration prevents it from being used in therapeutic settings. This study used a urethane-induced lung cancer model to assess the therapeutic potential of encapsulated AahII in chitosan nanoparticles (AahII-CNPs).Experimental Approach: To increase its biocompatibility and decrease its toxicity, AahII toxin was encapsulated in chitosan nanoparticles. AahII-CNPs were given intranasally to animals that present lung tumors caused by urethane. EGFR, Ki-67, BCL-2, and immune cell infiltration were among the markers used in immunohistochemical and molecular studies to evaluate the treatment’s effects on angiogenesis, proliferation, apoptosis, immunological response, and oxidative stress.Key Findings: Reduced expression of EGFR, Ki-67, and BCL-2 demonstrated that intranasal delivery of AahII-CNPs effectively prevented tumor angiogenesis and cell proliferation. Additionally, the formulation induced apoptosis and had immunomodulatory effects, as shown by a decrease in granulocyte infiltration and an increase in natural killer (NK) cell infiltration. Its anticancer activity was further enhanced by the restoration of oxidative balance in lung tissue by AahII-CNPs. Results demonstrate the therapeutic potential of AahII-CNPs as a new bioengineered formulation for lung cancer treatment.Conclusions: The chitosan encapsulation method of AahII’s targeted administration and decreased toxicity provide a viable approach to modifying important neoplastic pathways and boosting the host immune response. One promising option for more preclinical research in lung cancer treatment is AahII-CNPs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Merzouagui et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: